

Docket No. 25401-4

CERTIFICATE OF EXPRESS MAILING

Express label #: EL886352349US

Date of Deposit: December 21, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box Patent Application; U.S. Patent and Trademark Office; Washington, DC 20231.

Catherine L. Vigil

PATENT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Sabine Flicker et al : Paper No.:
Serial No.: To be assigned : Group Art Unit:
Filing Date: December 21, 2001 : Examiner:
For: **Allergen Specific IgE-Fabs and Use Thereof**

PRELIMINARY AMENDMENT

Box Patent Application
U.S. Patent and Trademark Office
Washington, DC 20231

Dear Sir:

Prior to calculation of the filing fee and first action by the Examiner, please amend the present application as follows:

In the Claims:

Please cancel claims 9-12.

Please amend claims 3-6 and 8 to read as follows:

3. (Amended) Group 2 allergen specific human IgG comprising the variable regions of the IgE Fabs of claim 1.
4. (Amended) IgE-Fabs according to claim 1, which are directed against Phl p 2.

5. (Amended) IgE-Fabs according to claim 1, which are recombinantly produced.

6. (Amended) A diagnostic reagent comprising the IgE-Fabs according to claim 1, and/or the corresponding complete antibodies, and/or modified versions of said Fabs and/or antibodies.

8. (Amended) A vaccine against type I allergy, comprising the IgE-Fabs according to claim 1, and/or the corresponding complete antibodies, and/or modified versions of said Fabs and/or antibodies.

Please add the following claims 13-24:

--13. (NEW) Group 2 allergen specific human IgG comprising the variable regions of the IgE Fabs of claim 2.--

--14. (NEW) IgE-Fabs according to claim 2, which are directed against Phl p 2.--

--15. (NEW) IgG according to claim 3, directed against Phl p 2.--

--16. (NEW) A diagnostic reagent comprising the IgE-Fabs according to claim 2, and/or the corresponding complete antibodies, and/or modified versions of said Fabs and/or antibodies.--

10027725-122101

--17. (NEW) A diagnostic reagent comprising the IgG according to claim 3, and/or the corresponding complete antibodies, and/or modified versions of said IgG and/or antibodies.--

--18. (NEW) A diagnostic kit comprising the reagent according to claim 16.--

--19. (NEW) A diagnostic kit comprising the reagent according to claim 17.--

--20. (NEW) A vaccine against type I allergy, comprising the IgE-Fabs according to claim 2, and/or the corresponding complete antibodies, and/or modified versions of said Fabs and/or antibodies.--

--21. (NEW) A method for passive immunotherapy of type I allergy, comprising administering Phl p 2-specific IgE-Fabs according to claim 1.--

--22. (NEW) A method for diagnosing type I allergy, comprising contacting a sample with Phl p 2-specific IgE-Fabs according to claim 1.--

--23. (NEW) A method for environmental allergen detection, comprising contacting a sample with Phl p 2-specific IgE-Fabs according to claim 1.--

--24. (NEW) A method for standardization of allergen extracts, comprising standardizing with Phl p 2-specific IgE-Fabs according to claim 1.--

REMARKS

By the present Amendment, claims 3-6 and 8 are amended to omit their multiple dependency and claims 9-12 are cancelled. Claims 13-24 are added. Claim 13 contains limitations from original claim 3, claims 14 and 15 contain limitations from original claim 4 and claims 16 and 17 contain limitations from original claim 6. Claims 18 and 19 contain limitations from original claim 7, claim 20 contains limitations from original claim 8 and claims 21-24 contain limitations from original claims 9-12, respectively. It is believed that these changes do not involve any introduction of new matter, whereby entry is believed to be in order and is respectfully requested.

Respectfully submitted,



Holly D. Kozlowski
Registration No. 30,468
Dinsmore & Shohl LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

745882.01

VERSION WITH MARKING SHOWING CHANGES MADE

In the Claims:

Claims 3-6 and 8 are amended as follows:

3. (Amended) Group 2 allergen specific human IgG comprising the variable regions of the IgE Fabs of claim 1 [claims 1 or 2].
4. (Amended) IgE-Fabs according to claim 1 [claims 1 or 2 or IgG according to claim 3], which are directed against Phl p 2.
5. (Amended) IgE-Fabs according to claim 1 [any of the claims 1-2 or 4 and IgG according to claims 3 or 4], which are recombinantly produced.
6. (Amended) A diagnostic reagent comprising the IgE-Fabs [and/or IgG] according to claim 1 [any of the claims 1-5], and/or the corresponding complete antibodies, and/or modified versions of said Fabs and/or antibodies.
8. (Amended) A vaccine against type I allergy, comprising the IgE-Fabs [and/or IgG] according to claim 1 [any of the claims 1-5], and/or the corresponding complete antibodies, and/or modified versions of said Fabs and/or antibodies.